Trade Report: The Ziopharm Oncology Inc. (ZIOP) Stake Boosted by Emerald Mutual Fund Advisers Trust

The Ziopharm Oncology Inc. (ZIOP) Stake Boosted by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust raised its position in Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 3.1% during the second quarter, Holdings Channel reports. The fund owned 596,693 shares of the biotechnology company’s stock after buying an additional 17,929 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Ziopharm Oncology were worth $3,276,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Commonwealth Equity Services Inc boosted its position in Ziopharm Oncology by 4.7% in the first quarter. Commonwealth Equity Services Inc now owns 46,575 shares of the biotechnology company’s stock worth $346,000 after buying an additional 2,109 shares during the last quarter. Pacad Investment Ltd. bought a new stake in shares of Ziopharm Oncology during the first quarter valued at about $138,000. TIAA CREF Investment Management LLC increased its stake in shares of Ziopharm Oncology by 4.5% in the first quarter. TIAA CREF Investment Management LLC now owns 447,313 shares of the biotechnology company’s stock valued at $3,319,000 after buying an additional 19,211 shares during the period. Stratos Wealth Partners LTD. bought a new stake in shares of Ziopharm Oncology during the first quarter valued at about $102,000. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock valued at $22,601,000 after buying an additional 17,982 shares during the period. Institutional investors and hedge funds own 44.95% of the company’s stock.

Ziopharm Oncology Inc. (NASDAQ:ZIOP) traded up 1.25% during midday trading on Friday, hitting $5.69. 986,285 shares of the stock were exchanged. Ziopharm Oncology Inc. has a 1-year low of $4.45 and a 1-year high of $14.93. The firm’s 50-day moving average price is $5.47 and its 200 day moving average price is $6.33. The firm’s market capitalization is $742.52 million.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. The firm earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The company’s quarterly revenue was up 525.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS. Analysts expect that Ziopharm Oncology Inc. will post ($1.34) earnings per share for the current fiscal year.

ZIOP has been the subject of several research reports. Griffin Securities restated a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a research report on Friday, July 1st. Zacks Investment Research upgraded shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Wednesday, July 27th. Wells Fargo & Co. upgraded shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Finally, Mizuho restated a “neutral” rating and set a $5.00 price objective (down from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $9.75.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Related posts

Leave a Comment